Stockscreener 앱 받기
1.01
5.61%
-0.06
시간 외 거래:
.99
-0.02
-1.98%
전일 마감가:
$1.07
열려 있는:
$1.05
하루 거래량:
91,720
Relative Volume:
0.70
시가총액:
$13.47M
수익:
$2.57M
순이익/손실:
$-15.44M
주가수익비율:
-0.3264
EPS:
-3.0946
순현금흐름:
$-24.67M
1주 성능:
-1.94%
1개월 성능:
-41.62%
6개월 성능:
-68.63%
1년 성능:
-84.41%
1일 변동 폭
$1.00
$1.0686
1주일 범위
$0.97
$1.08
52주 변동 폭
$0.93
$7.23
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
1.01 | 13.47M | 2.57M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-06-08 | 개시 | H.C. Wainwright | Buy |
| 2026-04-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference - GlobeNewswire Inc.
Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com
Lucid Capital Markets initiates Tvardi stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com India
Lucid Capital Markets initiates Tvardi stock with buy rating - Investing.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Barchart.com
Tvardi Therapeutics to Participate in Upcoming Investor Events - Barchart.com
Tvardi (TVRD) Q1 2026 Results: The EPS Result Is Above Expectation in the Latest Reading; After Earnings: Shares Close 2.25% Higher in Latest TradingEarnings Whisper Number - vinanet.vn
Tvardi Therapeutics (TVRD) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
Tvardi (TVRD) Shares: Finishes 2.66% Down at $1.83 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.74 to $1.92 on the DayFlat Correction - vinanet.vn
BTIG Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative ColitisSlideshow - Seeking Alpha
Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data - TradingView
Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety - TradingView
Tvardi Therapeutics: TTI-109 offers targeted STAT3 inhibition with improved safety and efficacy for UC and HCC - TradingView
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot - Investing.com
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot By Investing.com - Investing.com UK
H.C. Wainwright reiterates Tvardi stock rating citing UC pivot - Investing.com
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Moomoo
Tvardi Therapeutics increases ATM offering to $9.69M - scanx.trade
Tvardi Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Tvardi Q2 net loss reaches $6.5 million - grafa.com
H.C. Wainwright Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Tvardi Therapeutics Reports Q2 2026 Net Loss of $6.5 Million - Minichart
Tvardi stock falls as investors book gains after Phase 1 data - scanx.trade
Tvardi Therapeutics | 8-K: Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - Moomoo
Tvardi Q2 EPS $(0.69) beats $(0.70) estimate, loss narrows 31% - scanx.trade
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Tvardi Therapeutics, Inc. 2026: Revenue ($6.46M), EPS ($0.69) — 10-Q Summary - TradingView
Form 8K Tvardi Therapeutics Inc For: 14 August By Investing.com - Investing.com Canada
Tvardi Reports Positive TTI-109 Data, Picks Ulcerative Colitis for Next-Gen Drug - Minichart
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Q2 2026 saw a $6.5M net loss, cash of $15.8M, and urgent need for additional funding - TradingView
Tvardi posts Q2 2026 net loss of $6.5M, cash $15.8M; reports TTI-109 healthy volunteer topline - TradingView
Tvardi Therapeutics Reports Topline Healthy Volunteer Results for TTI-109 and Selects Ulcerative Colitis as Initial Indication - Quiver Quantitative
Tvardi Reports $6.5 Million Second-Quarter Net Loss and TTI-109 UC Plans - Quiver Quantitative
Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million - TradingView
Tvardi: Q2 Earnings Snapshot - KTVB
BRIEF-Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million - TradingView
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - Yahoo Finance
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
Tvardi Therapeutics (TVRD) Holds Ground at $1.77 Amid Cautious Biotech SentimentBullish Pattern Stocks - Vinanet
Tvardi Therapeutics (TVRD) Holds Ground at $1.77 Amid Cautious Biotech SentimentIndex Put Call - dars.gov.et
Tvardi Therapeutics to Host KOL Webinar on the Clinical - GlobeNewswire
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Tvardi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Enterprise value to revenue forward of Tvardi Therapeutics Inc. – FWB:69C - TradingView
TVRD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tvardi Therapeutics Ord Shs (TVRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tvardi Therapeutics Inc (TVRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):